To investigate whether the effects of LTβR in preclinical models are applicable to patient HCC and whether it can increase sensitivity to immunotherapy with glycolytic inhibitors, we created patient-derived orthotopic xenograft (PDOX) models and treated them with two FDA-approved glycolysis inhibitors: Alkannin (PKM2 inhibitor) and WZB117 (GLUT1 inhibitor). This evidence concerns the gene LTBR and hepatocellular carcinoma.